Novel uses

Abstract

This invention relates to the new use of the compound (I) or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing it for the treatment of pruritus and to combinations for such a use.

1 . A method of treatment of chronic pruritus, wherein the pruritus is due to or associated with autoimmune dermatoses which comprises
 administering to a human in need thereof an effective amount of 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-((8aS)-6-oxo-hexahydro-pyrrolo[1,2-α]-pyrazin-2-yl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylarnide or a pharmaceutically acceptable salt thereof.   
     
     
         2 . A method as claimed in  claim 1  wherein autoimmune dermatoses are selected from bullous dermatoses, dermatitis herpetiformis Duhring, bullous pemphigoid, dermatomyositis and epidermolysis bullosa, 
     
     
         3 . A method of treatment according to  claim 1 , wherein the pharmaceutically acceptable salt of the compound is maleate. 
     
     
         4 . A method of treatment according to  claim 1 , wherein the compound is orvepitant maleate as anhydrous crystalline. 
     
     
         5 . A method of treatment according to  claim 1 , wherein the compound is orvepitant maleate as anhydrous crystalline form characterized in that it provides an X-ray powder diffraction (XRD) pattern expressed in terms of 2 theta angles and obtained with a diffractometer using copper Kα X-radiation, wherein the XRD pattern comprises 2 theta angle peaks at essentially at 7.3±0.1, 7.5±0.1, 10.9±0.1, 12.7±0.1, 16.5±0.1 degrees, which correspond respectively to d-spacings at 12.2, 11.8, 8.1, 7.0 and 5.4 Angstroms (Å), characterized in that it provides an X-ray powder diffraction (XRD) pattern expressed in terms of 2 theta angles and obtained with a diffractometer using copper Kα X-radiation, wherein the XRD pattern comprises 2 theta angle peaks at essentially at 7.31:0.1, 7.5±0.1, 10.9±0.1, 12.7±0.1, 16.5±0.1 degrees, which correspond respectively to d-spacings at 12.2, 11.8, 8.1, 7.0 and 5.4 Angstroms (Å).